Immunogenicity and efficacy of pembrolizumab and doxorubicin in a phase I trial for patients with metastatic triple-negative breast cancer
Authors:
Open Access
- 9 June 2023
- journal article
- research article
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 72 (9) , 3013-3027
Abstract
Currently there is a limited understanding for the optimal combination of immune checkpoint inhibitor and chemotherapy for patients with metastatic triple-negative breast cancer (mTNBC). Here we evaluate the safety, efficacy, and immunogenicity of a phase I trial for patients with mTNBC treated with pembrolizumab plus doxorubicin. Patients without prior anthracycline use and 0–2 lines of prior systemic chemotherapies received pembrolizumab and doxorubicin every 3 weeks for 6 cycles followed by pembrolizumab maintenance until disease progression or intolerance. The primary objectives were safety and objective response rate per RECIST 1.1. Best responses included one complete response (CR), five partial responses (PR), two stable disease (SD), and one progression of disease (PD). Overall response rate was 67% (95% CI 13.7%, 78.8%) and clinical benefit rate at 6 months was 56% (95% CI 21.2%, 86.3%). Median PFS was 5.2 months (95% CI 4.7, NA); median OS was 15.6 months (95% CI 13.3, NA). Grade 3–4 AEs per CTCAE 4.0 were neutropenia n = 4/10 (40%), leukopenia n = 2/10 (20%), lymphopenia n = 2/10 (20%), fatigue n = 2/10 (20%), and oral mucositis n = 1/10 (10%). Immune correlates showed increased frequencies of circulating CD3 + T cells (p = 0.03) from pre-treatment to cycle 2 day 1 (C2D1). An expansion of a proliferative exhausted-like PD-1 + CD8 + T cell population was identified in 8/9 patients, and exhausted CD8 + T cells were significantly expanded from pre-treatment to C2D1 in the patient with CR (p = 0.01). In summary, anthracycline-naïve patients with mTNBC treated with the combination of pembrolizumab and doxorubicin showed an encouraging response rate and robust T cell response dynamics.Trial registration: NCT02648477.Keywords
Funding Information
- Circle 1500
- National Institutes of Health (RO1CA206911)
- Cedars-Sinai Medical Center
This publication has 47 references indexed in Scilit:
- Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapyNature Medicine, 2014
- The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014Annals of Oncology, 2014
- PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumorsJournal of Clinical Investigation, 2014
- Doxorubicin Eliminates Myeloid-Derived Suppressor Cells and Enhances the Efficacy of Adoptive T-Cell Transfer in Breast CancerCancer Research, 2014
- Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancerCell Death & Differentiation, 2013
- Anthracyclines in the management of metastatic breast cancer: state of the artEuropean Journal of Cancer Supplements, 2011
- Pivotal Role of Innate and Adaptive Immunity in Anthracycline Chemotherapy of Established TumorsCancer Research, 2011
- Doxorubicin downregulates cell surface B7-H1 expression and upregulates its nuclear expression in breast cancer cells: role of B7-H1 as an anti-apoptotic moleculeBreast Cancer Research, 2010
- Triple-Negative Breast Cancer: Clinical Features and Patterns of RecurrenceClinical Cancer Research, 2007
- Caspase-dependent immunogenicity of doxorubicin-induced tumor cell deathJournal of Experimental Medicine, 2005